119435-90-4

Usage

Uses

Used in Pharmaceutical Industry:
6-(Bromomethyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene is used as an intermediate in the synthesis of pharmaceuticals for its versatile chemical properties, enabling the development of various medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 6-(Bromomethyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene serves as an intermediate for the synthesis of agrochemicals, contributing to the creation of effective crop protection agents and other agricultural products.
Used in Organic Synthesis:
6-(Bromomethyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene is utilized as a key intermediate in organic synthesis, allowing for the production of a wide range of organic compounds for various applications.
It is crucial to handle this chemical with care due to its potentially hazardous nature if not properly used and stored.

InChI:InChI=1/C15H21Br/c1-14(2)7-8-15(3,4)13-9-11(10-16)5-6-12(13)14/h5-6,9H,7-8,10H2,1-4H3

Upstream product

• 6683-48-3 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphthalene 
• 34241-39-9 azobisisobutyronitrile 
• 167958-79-4 1,1,4,4,6-pentamethyl-1,4-dihydronaphthalene 

Downstream Products

• 119435-91-5 2-(4-Carbomethoxyphenyl)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propionic acid 
• 119436-52-1 (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)methyl-triphenyl-phosphonium bromide 
• 119436-72-5 4-[(4S,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid methyl ester 
• 119436-73-6 4-[(4R,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid methyl ester 
• 119436-11-2 4-[(4S,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid 
• 119436-12-3 4-[(4R,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid 
• 119436-69-0 Methyl threo-4-<1,2-dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoate 
• 119436-70-3 Methyl erythro-4-<1,2-dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoate 
• 119436-08-7 threo-4-<1,2-Dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoic acid 
• 119436-09-8 erythro-4-<1,2-Dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoic acid 
• 102121-54-0 Methyl (E)-4-<2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethenyl>benzoate 
• 119436-53-2 methyl 4-((Z)-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-6-yl)vinyl)benzoate 
• 119436-55-4 2-(4-Carbomethoxyphenyl)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propionyl chloride 

Relevant academic research and scientific papers

Tricyclic hydroxamate and benzaminde derivatives, compositions and methods

The present invention relates to compounds and methods for inhibiting histone deacetylase enzymatic activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit histone deacetylases (HDACs), and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, and also central nervous system diseases. It further deals with processes for preparing said compounds.

Aromatic polycyclic retinoid-type derivatives, method for preparing same, and use thereof for making pharmaceutical and cosmetic compositions

Novel aromatic polycyclic retinoid-type derivatives of general formula (I), wherein groupings R3and R4attached to the double bond between carbons 11 and 12 are cis groupings, and pharmaceutical and cosmetic compositions containing same, are disclosed.

Aromatic keto compounds, the preparation thereof, and drugs and cosmetics containing these

Compounds of the general formula I STR1

Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids

Alkyl-substituted azobenzene-4-carboxylic acids are potent differentiation inducers of human promyelocytic leukemia cell line HL-60 to mature granulocytes. Their structure-activity relationships are very similar to those of other retinoidal benzoic acids which are generally represented by 4 and named retinobenzoic acids. The structure-activity relationships of azobenzenecarboxylic acids can also be applied to the known retinoid TTNPB (3). Thus, (E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid (St30 (28)), and (E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid (St40) (29)), the acyclic alkyl analogues of TTNPB, are nearly as active as retinoic acid. Among the oxidatively derived compounds (Az90, Ep series and Ox series) of azobenzene- or stilbenecarboxylic acids, Az90 (71) and Ep80 (61) have strong activities. However, all the bishydroxylated derivatives of TTNPB are inactive, while a diketo analogue Ox580 (69) has only weak potency. The activities of conformationally restricted compounds of TTNPB offer some information on the stereochemistry of the active form of these retinoidal compounds.